Patient biology is the key to unlocking insights that can help us better discover and develop treatments for some of today’s most challenging and debilitating diseases...
NEW YORK (PRWEB) September 14, 2018
Today, Mediaplanet announces the launch of this September’s edition of “Rare Diseases." This campaign showcases the innovative work being done within rare diseases research diagnostics and highlights what industry experts and patients see as potential future therapies for those living with rare diseases.
The print component of "Rare Diseases" is distributed in this weekend's edition of USA Today in New York, San Francisco, Los Angeles, Chicago, Boston, Seattle and Houston, with a circulation of approximately 250,000 copies and an estimated readership of 750,000. The digital component is distributed nationally, through a vast social media strategy and across a network of top news sites and partner outlets. To explore the digital version of the campaign, click here.
One notable supporter of the "Rare Diseases" campaign is BERG – a Boston-based biotech founded on the idea of challenging the status quo in drug development. By leveraging its proprietary intelligence platform, Interrogative Biology®, BERG harnesses artificial intelligence (AI) and biological understanding of diseases to potentially identify new pathways and treatment targets in oncology, neurology and rare diseases. This unique approach to reinventing drug discovery and development has given BERG the opportunity to more rapidly develop a robust pipeline of first-in-class product candidates that have the potential to improve patient and caregivers’ lives.
“Patient biology is the key to unlocking insights that can help us better discover and develop treatments for some of today’s most challenging and debilitating diseases,” said Niven R. Narain, Ph.D., Co-Founder, President & Chief Executive Officer of BERG. “As we continue to identify and understand biomarkers of disease activity, we aim to more effectively personalize medicine as well as advance novel treatment options for patients and caregivers more quickly and cost-effectively than that of traditional methods.”
In May 2018, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for BERG’s leading topical product candidate, BPM 31510 (ubidecarenone), for the treatment of epidermolysis bullosa (EB), a rare, pervasive and debilitating connective tissue disorder. According to Debra of America, the only U.S. nonprofit providing all-inclusive support to the EB community, an estimated 25,000 people are living with EB and nearly 200 children are born each year with the disease.
“Epidermolysis Bullosa, which is commonly referred to as ‘the worst disease you’ve never heard of’, currently lacks any FDA-approved treatment or cure specifically for EB,” added Dr. Narain. “We’re encouraged by the results of our ongoing research of BPM 31510 being conducted at the University of Miami and are committed to delivering breakthrough therapies to make a difference in the lives of these patients.”
Additional information on this clinical trial and participating sites can be found on ClinicalTrials.gov using the identifier NCT02793960.
This campaign was made possible with the support of National Organization for Rare Disorders (NORD), BERG LLC, NFL Green Bay Packer Clay Matthews, CureDuchenne, PTC Therapeutics, Boehringer Ingelheim, Incyte, Strongbridge Biopharma, Progenics Pharmaceuticals, Horizon Pharma, Cytokinetics, Retrophin, Centogene, Dante Labs, Global Genes, Rare Disease United Foundation, Chloe’s Fight Rare Disease Foundation, Rare & Undiagnosed Network, RUN’s NBA Initiative, and Cheyanna's Champions 4 Children.
ABOUT BERG:
BERG LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology®, to map disease and revolutionize treatments across oncology, neurology and rare diseases. By taking a Back to Biology™ approach, BERG is able to identify critical biomarkers that can accelerate the discovery and development of treatments aimed at the most promising therapeutic targets and pathways. BERG has leveraged both Interrogative Biology® and traditional R&D methods to develop a robust pipeline of first-in-class product candidates and diagnostics that advance bold innovations that have the potential to improve patient lives. To learn more about how we’re enabling bold innovation, visit berghealth.com.
About Mediaplanet
Mediaplanet is the leading independent publisher of content marketing campaigns covering a variety of topics and industries such as Health, Education, Lifestyle, Business and Technology, and Corporate Social Responsibility. We turn consumer interest into action by providing readers with motivational editorial, pairing it with relevant advertisers and distributing it within top newspapers and online platforms around the world. Please visit http://www.mediaplanet.com for more on who we are and what we do.
Mediaplanet Press Contact:
Sarah Wasser
sarah.wasser@mediaplanet.com
(646) 979-2831
BERG Media Contact:
Chris Dougherty
Ogilvy
917-515-9876
BERG@Ogilvy.com
BERG Investor Contact:
Molly Cameron
BERG
617-588-1000
Molly.Cameron@BergHealth.com